Sotatercept illustration courtesy of the New England Journal of Medicine.
The FDA is expected to base its decision in part on the STELLAR clinical trial, which included 163 adult patients treated with subcutaneous sotatercept and 160 patients treated with a placebo.
How common is it for patients to present with overlapping cardiac, renal and metabolic issues? A new analysis in JAMA Cardiology explored that very question.
The University of Rochester is part of a growing trend where academic medical centers are partnering with venture capital firms to implement new technologies that improve patient care.